spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  cervical cancer vaccine 

 HSMN NewsFeed - 14 Sep 2015
POZEN Appoints James P. Tursi, M.D. Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Mar 2015
Innocoll AG Appoints James Tursi, M.D., as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Oct 2009
FDA Approves Cervarix, GlaxoSmithKline's Cervical Cancer Vaccine
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 28 Sep 2009
CSL Biotherapies Reaches Agreement with Merck & Co. on Rights to Market and Distribute Afluria(R) in the U.S.
Biopharmaceuticals Distribution
 HSMN NewsFeed - 9 Sep 2009
FDA Advisory Committee Makes Favorable Recommendation for Cervarix, GlaxoSmithKline's Candidate Cervical Cancer Vaccine
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 13 Nov 2008
GARDASIL®, Merck's Cervical Cancer Vaccine, Demonstrated Efficacy in Preventing HPV-Related Disease in Males in Phase III Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Jun 2008
GlaxoSmithKline Responds to FDA on CERVARIX(R) and Plans to Submit Final Study Data for Approval
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 25 Jun 2008
Merck & Co., Inc Receives Complete Response Letter from the Food and Drug Administration for Use of GARDASIL(R) in Women Ages 27 through 45
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 14 May 2008
CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date
Biopharmaceuticals
 HSMN NewsFeed - 19 Mar 2008
Supplemental Application for GARDASIL(R), Merck's Cervical Cancer Vaccine, Designated Priority Review by the U.S. FDA for Use in Women 27 through 45
Biopharmaceuticals
 HSMN NewsFeed - 10 Mar 2008
GSK Cervical Cancer Candidate Vaccine CERVARIX (R) Demonstrates Long-Term Protection for More Than Six Years
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Dec 2007
GlaxoSmithKline Receives FDA 'Complete Response' Letter for Cervical Cancer Vaccine
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Nov 2007
New Data Presented on GARDASIL(R), Merck's Cervical Cancer Vaccine, in Women Through Age 45
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Sep 2007
Merck to Donate Three Million Doses of Gardasil(R), its Cervical Cancer Vaccine, to Support Vaccination Programs in Lowest Income Nations
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Jul 2007
GSK's Cervical Cancer Candidate Vaccine Cervarix(TM) Receives Positive Opinion in Europe for Prevention of Cervical Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 27 Jun 2007
Largest Cervical Cancer Vaccine Efficacy Trial Shows CERVARIX(R) Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
Biopharmaceuticals
 HSMN NewsFeed - 20 Jun 2007
Merck Provides Update on Status of Supplemental Biologics License Applications (sBLA) for GARDASIL(R)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Jun 2007
CERVARIX(R), the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 May 2007
Data Published in The Lancet Show GARDASIL(R) was 100 Percent Effective in Preventing High-Grade Vulvar and Vaginal Lesions Caused by HPV Types 16 and 18
Biopharmaceuticals
 HSMN NewsFeed - 9 May 2007
New England Journal of Medicine Publishes New Data on GARDASIL(R), Merck's Cervical Cancer Vaccine
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Apr 2007
CERVARIX(R), GSK Cervical Cancer Candidate Vaccine, Demonstrates 100 Percent Protection Against Precancerous Lesions Caused By Cancer-Causing Human Papillomavirus Types 16 & 18 for More Than Five Years
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Apr 2007
Merck Submits New Cross-Protection Data for GARDASIL(R) to the FDA and Seeks New Indications for Vaginal and Vulvar Cancers
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 17 Apr 2007
Advaxis Completes Dosing and Enrollment of Third Cohort of Patients in Phase I/II Cervical Cancer Vaccine Trial
Biopharmacetuicals Oncology
 HSMN NewsFeed - 29 Mar 2007
GlaxoSmithKline Submits Biologics License Application to U.S. Food and Drug Administration for CERVARIX(R)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 22 Mar 2007
CDC Finalizes Advisory Panel Recommendations for GARDASIL(R), Merck's Cervical Cancer Vaccine
Biopharmaceuticals
 HSMN NewsFeed - 18 Jan 2007
GlaxoSmithKline Initiates Head-to-Head Study of Cervical Cancer Vaccines
Biopharmaceuticals
 HSMN NewsFeed - 13 Nov 2006
Merck Launches National Advertising Campaign for GARDASIL(R), Merck's New Cervical Cancer Vaccine
Biopharmaceuticals
 HSMN NewsFeed - 1 Nov 2006
Merck's Cervical Cancer Vaccine, GARDASIL(R), Added to the CDC Vaccines for Children Contract
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Oct 2006
Mathematical Model Based on Clinical Findings From Cervarix(TM), GSK's Cervical Cancer Candidate Vaccine, Suggests Vaccination Could Reduce Cervical Cancers by up to 80%
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Sep 2006
Mathematical Model Predicts That CERVARIX May Prevent Nearly 80 Percent of Cervical Cancers
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Sep 2006
Carrington Subsidiary to Develop Needle-less Delivery of Cervical Cancer Vaccine With the National Cancer Institute (NCI)
Biopharmaceuticals Drug Delivery Oncology
 HSMN NewsFeed - 22 Sep 2006
European Commission Approves GARDASIL(R), Merck's Cervical Cancer Vaccine
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 28 Jul 2006
GARDASIL(R), Merck's Cervical Cancer Vaccine, Receives Positive Opinion from the European Medicines Agency
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 12 Jul 2006
Latest Data Confirm GlaxoSmithKline's Proprietary Adjuvant System For Cervarix(TM) Induces a Stronger and More Sustained Immune Response Than a Conventional Adjuvant Formulation
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Jun 2006
GlaxoSmithKline Applauds ACIP for New Guidance on Use of HPV Vaccine to Protect Girls and Women Against Cervical Cancer
Biopharmaceuticals
 HSMN NewsFeed - 29 Jun 2006
Merck's New Cervical Cancer Vaccine, GARDASIL(R), Unanimously Recommended by CDC Advisory Panel for Vaccination of Girls and Women 11 to 26 Years
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Jun 2006
FDA Approves Merck's GARDASIL(R), the World's First and Only Cervical Cancer Vaccine
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Jun 2006
New Data Show Cervarix(TM), GSK's HPV 16/18 Cervical Cancer Candidate Vaccine, Is Highly Immunogenic and Well-Tolerated In Women Over 25 Years of Age
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 May 2006
FDA Approves ZOSTAVAX(R), Merck's New Vaccine for Prevention of Shingles in Adults Age 60 and Older
Biopharmaceuticals FDA
 HSMN NewsFeed - 18 May 2006
FDA Advisory Committee Votes Unanimously That Clinical Data Support the Efficacy and Safety of GARDASIL(R), Merck's Investigational Cervical Cancer Vaccine
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Apr 2006
Cervarix(TM), GSK's Candidate Vaccine for Cervical Cancer, Demonstrated Sustained Efficacy for up to 4.5 Years and Broader Protection Against Cancer- Causing HPV Types
Biopharmaceuticals
 HSMN NewsFeed - 7 Feb 2006
GARDASIL(R), Merck's Investigational Cervical Cancer Vaccine, to Receive Priority Review from the U.S. Food and Drug Administration
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Feb 2006
FDA Approves Merck's ROTATEQ(R), The Only Vaccine in the U.S. to Prevent Rotavirus Gastroenteritis, a Leading Cause of Severe Infant Diarrhea
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Jan 2006
In a New Study Published in New England Journal of Medicine, ROTATEQ(R), Merck's Investigational Rotavirus Vaccine, Prevented 98 Percent of Severe Rotavirus Gastroenteritis
Biopharmaceuticals Gastroenterology
Return to NewsFeed  

 Additional items found! 6

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 6 additional stories matching:
cervical cancer vaccine
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.